ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Wilson Disease
Gene/Gene Panel: ATP7B
Context: Adult
Date
Status
Outcomes-Interventions
Notes
2024/03/24
Released
1.2.4
Morbidity and mortality from copper deposition (GroupA)
Referral to specialist for evaluation and to guide appropriate therapy including diet, copper chelation and zinc therapy (GroupA) 10CA
System migration to fix the sem versioning
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
ATP7B 0010200 WILSON DISEASE; WND
Strong Actionability
Strong Actionability
2024/03/24
Released (Under revision)
Morbidity and mortality from copper deposition (GroupA)
Referral to specialist for evaluation and to guide appropriate therapy including diet, copper chelation and zinc therapy (GroupA) 10CA
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
ATP7B 0010200 WILSON DISEASE; WND
Strong Actionability
Strong Actionability
2022/07/18
Released
Morbidity and mortality from copper deposition (GroupA)
Referral to specialist for evaluation and to guide appropriate therapy including diet, copper chelation and zinc therapy (GroupA) 10CA
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
ATP7B 0010200 WILSON DISEASE; WND
Strong Actionability
Strong Actionability
2022/05/24
Released (Under revision)
1.2.2
Liver disease (GroupA)
Chelation/zinc therapy (GroupA) 10DA
Neuropsychiatric disease (GroupA)
Chelation/zinc therapy (GroupA) 10DA
Internal system migration associated with MONDO name addition.
2022/02/09
Released
1.2.2
Liver disease (GroupA)
Chelation/zinc therapy (GroupA) 10DA
Neuropsychiatric disease (GroupA)
Chelation/zinc therapy (GroupA) 10DA
Internal system migration associated with MONDO name addition.
2022/02/09
Released (Under revision)
1.2.1
Liver disease (GroupA)
Chelation/zinc therapy (GroupA) 10DA
Neuropsychiatric disease (GroupA)
Chelation/zinc therapy (GroupA) 10DA
MONDO IDs added, scoring groups unadjusted.
2020/12/23
Released
1.2.1
Liver disease (GroupA)
Chelation/zinc therapy (GroupA) 10DA
Neuropsychiatric disease (GroupA)
Chelation/zinc therapy (GroupA) 10DA
MONDO IDs added, scoring groups unadjusted.
2020/02/19
Released (Under revision)
1.2.0
Liver disease (GroupA)
Chelation/zinc therapy (GroupA) 10DA
Neuropsychiatric disease (GroupA)
Chelation/zinc therapy (GroupA) 10DA
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
1.2.0
Liver disease (GroupA)
Chelation/zinc therapy (GroupA) 10DA
Neuropsychiatric disease (GroupA)
Chelation/zinc therapy (GroupA) 10DA
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/04/04
Released
1.1.0
Liver disease
Chelation/zinc therapy 10DA
Neuropsychiatric disease
Chelation/zinc therapy 10DA
Internal system migration related to merging adult and pediatric contexts.
2018/11/01
Released
1.0.2
Liver disease
Chelation/zinc therapy 10DA
Neuropsychiatric disease
Chelation/zinc therapy 10DA
Internal system migration related to score text replacement from E to N
2018/01/11
Released
1.0.1
Liver disease
Chelation/zinc therapy 10DA
Neuropsychiatric disease
Chelation/zinc therapy 10DA
2017/11/01
Released
1.0.0
Liver disease
Chelation/zinc therapy 10DA
Neuropsychiatric disease
Chelation/zinc therapy 10DA
¤ Powered by BCM's Genboree.